In Vitro Evaluation of the Activities of the Novel Anticytomegalovirus Compound AIC246 (Letermovir) against Herpesviruses and Other Human Pathogenic Viruses | Zendy

Manfred Marschall | Zendy; Thomas Stamminger | Zendy; Andreas Urban | Zendy; Steffen Wildum | Zendy; Helga RuebsamenSchaeff | Zendy; Holger Zimmermann | Zendy; Peter Lischka | Zendy

Open Access

In Vitro Evaluation of the Activities of the Novel Anticytomegalovirus Compound AIC246 (Letermovir) against Herpesviruses and Other Human Pathogenic Viruses

Author(s) -

Manfred Marschall,

Thomas Stamminger,

Andreas Urban,

Steffen Wildum,

Helga RuebsamenSchaeff,

Holger Zimmermann,

Peter Lischka

Publication year - 2011

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.05908-11

Subject(s) - in vitro , virology , biology , human herpesvirus , microbiology and biotechnology , virus , genetics

AIC246 (letermovir) is a potent anticytomegalovirus drug in clinical development. Here, we report a consistent antiviral efficacy of AIC246 against human cytomegalovirus laboratory strains, clinical isolates, and virus variants resistant to approved drugs. Furthermore, we describe a remarkable selectivity of AIC246 for human cytomegaloviruses compared to that of other alpha-, beta-, or gammaherpesviruses or nonrelated pathogenic viruses, including adeno-, hepadna-, retro-, orthomyxo-, and flaviviruses. Our data confirm and support an excellent and selective anticytomegaloviral activity of AIC246.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research